These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1335 related articles for article (PubMed ID: 24076216)

  • 21. Sophocarpine inhibits tumor progression by antagonizing the PI3K/AKT/mTOR signaling pathway in castration-resistant prostate cancer.
    Weng M; Shi C; Han H; Zhu H; Xiao Y; Guo H; Yu Z; Wu C
    PeerJ; 2022; 10():e14042. PubMed ID: 36132221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD44 variant 6 is associated with prostate cancer growth and chemo-/radiotherapy response in vivo.
    Ni J; Cheung BB; Beretov J; Duan W; Bucci J; Malouf D; Graham P; Li Y
    Exp Cell Res; 2020 Mar; 388(2):111850. PubMed ID: 31954695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
    Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
    Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CEACAM6 promotes gastric cancer invasion and metastasis by inducing epithelial-mesenchymal transition via PI3K/AKT signaling pathway.
    Zang M; Zhang B; Zhang Y; Li J; Su L; Zhu Z; Gu Q; Liu B; Yan M
    PLoS One; 2014; 9(11):e112908. PubMed ID: 25398131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways.
    Leu WJ; Swain ShP; Chan SH; Hsu JL; Liu SP; Chan ML; Yu CC; Hsu LC; Chou YL; Chang WL; Hou DR; Guh JH
    Oncotarget; 2016 Nov; 7(47):76995-77009. PubMed ID: 27769069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
    Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
    Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
    Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
    Gene; 2019 May; 698():50-60. PubMed ID: 30822475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. γ-Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway.
    Li Y; Wu T; Wang Y; Yang L; Hu C; Chen L; Wu S
    Gynecol Oncol; 2018 Apr; 149(1):163-172. PubMed ID: 29429592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
    Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
    Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GABARAPL1 suppresses metastasis by counteracting PI3K/Akt pathway in prostate cancer.
    Su W; Li S; Chen X; Yin L; Ma P; Ma Y; Su B
    Oncotarget; 2017 Jan; 8(3):4449-4459. PubMed ID: 27966458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CAV-1 contributes to bladder cancer progression by inducing epithelial-to-mesenchymal transition.
    Liang W; Hao Z; Han JL; Zhu DJ; Jin ZF; Xie WL
    Urol Oncol; 2014 Aug; 32(6):855-63. PubMed ID: 24968949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
    Shukla S; Maclennan GT; Hartman DJ; Fu P; Resnick MI; Gupta S
    Int J Cancer; 2007 Oct; 121(7):1424-32. PubMed ID: 17551921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MiR-129 inhibits cell proliferation and metastasis by targeting ETS1 via PI3K/AKT/mTOR pathway in prostate cancer.
    Xu S; Ge J; Zhang Z; Zhou W
    Biomed Pharmacother; 2017 Dec; 96():634-641. PubMed ID: 29035829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epithelial cell-derived periostin functions as a tumor suppressor in gastric cancer through stabilizing p53 and E-cadherin proteins via the Rb/E2F1/p14ARF/Mdm2 signaling pathway.
    Lv H; Liu R; Fu J; Yang Q; Shi J; Chen P; Ji M; Shi B; Hou P
    Cell Cycle; 2014; 13(18):2962-74. PubMed ID: 25486483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GOLM1 promotes prostate cancer progression through activating PI3K-AKT-mTOR signaling.
    Yan G; Ru Y; Wu K; Yan F; Wang Q; Wang J; Pan T; Zhang M; Han H; Li X; Zou L
    Prostate; 2018 Feb; 78(3):166-177. PubMed ID: 29181846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ginkgolic Acid Inhibits Invasion and Migration and TGF-β-Induced EMT of Lung Cancer Cells Through PI3K/Akt/mTOR Inactivation.
    Baek SH; Ko JH; Lee JH; Kim C; Lee H; Nam D; Lee J; Lee SG; Yang WM; Um JY; Sethi G; Ahn KS
    J Cell Physiol; 2017 Feb; 232(2):346-354. PubMed ID: 27177359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
    Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
    Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TROP2 promotes proliferation, migration and metastasis of gallbladder cancer cells by regulating PI3K/AKT pathway and inducing EMT.
    Li X; Teng S; Zhang Y; Zhang W; Zhang X; Xu K; Yao H; Yao J; Wang H; Liang X; Hu Z
    Oncotarget; 2017 Jul; 8(29):47052-47063. PubMed ID: 28423362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GPCR48/LGR4 promotes tumorigenesis of prostate cancer via PI3K/Akt signaling pathway.
    Liang F; Yue J; Wang J; Zhang L; Fan R; Zhang H; Zhang Q
    Med Oncol; 2015 Mar; 32(3):49. PubMed ID: 25636507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 67.